China SXT Pharmaceuticals, Inc. Announces Share Consolidation
Outstanding options, warrants and other rights to purchase Class A shares will be adjusted proportionately.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
China SXT Pharmaceuticals (NASDAQ: SXTC) will consolidate its Class A ordinary shares at a 1-for-100 ratio, effective October 26, 2026.
Post-consolidation trading is expected to begin at market opening that day under the same ticker. Class A shares outstanding will change from 68,677,498 to approximately 686,775, with fractional shares rounded up to the next whole share. The consolidation applies only to Class A shares; the 2 Class B shares will remain unchanged.
News Explained
The company is authorized to issue ordinary shares without a stated numerical ceiling for either class.
The announced consolidation is scheduled for
Details
Market move: SXTC -28.63% vs previous close. 1-for-100 share consolidation
On Oct 22, the day this news came out, the latest delayed price for SXTC is 28.63% below the previous close. Our momentum scanner has recorded 58 alerts for this stock so far that day. The latest delayed price is $0.05. Relative volume is very high at 4.4x the average.
Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.
Key Figures
- Consolidation ratio
- 1-for-100
- Class A ordinary shares
- Effective date
- October 26, 2026
- Share consolidation
- Class A shares outstanding before consolidation
- 68,677,498 shares
- Prior to the share consolidation
Key Terms
cusip financial
AI-generated analysis. How Rhea-AI works. Not financial advice.
TAIZHOU,
Prior to the Share Consolidation, 68,677,500 ordinary shares, consisting of 68,677,498 Class A ordinary shares and 2 Class B ordinary shares, are issued and outstanding. As a result of the Share Consolidation, every 100 Class A ordinary shares (or part thereof) will be combined into one (1) share, with fractional shares rounded up to the next whole share, and approximately 686,775 Class A ordinary shares and 2 Class B ordinary shares will be issued and outstanding after the Share Consolidation. The Share Consolidation will apply only to the Class A ordinary shares, and the Class B ordinary shares will not be affected and will remain unchanged. The Company is authorized to issue unlimited ordinary shares consisting of Class A ordinary shares, no par value per share, and Class B ordinary shares, no par value per share. All outstanding stock options, warrants and other rights to purchase the Company's Class A ordinary shares will be adjusted proportionately as a result of the Share Consolidation.
Upon the effectuation of the Share Consolidation, shareholders holding shares through a bank, broker or other nominee will have their shares automatically adjusted to reflect the Share Consolidation. Beneficial holders may contact their bank, broker or nominee for more information. Please direct any questions to your broker or the Company's transfer agent, Transhare Corporation, by calling +1 303-662-1122.
About China SXT Pharmaceuticals, Inc.
Founded in 2005 and headquartered in Taizhou City, Jiangsu Province, China, China SXT Pharmaceuticals, Inc. is an innovative pharmaceutical company focusing on the research, development, manufacture, marketing and sales of traditional Chinese medicine pieces, which is a type of Traditional Chinese Medicine that has been processed to be ready for use. For more information, please visit www.sxtchina.com.
Forward-Looking Statements
Certain statements in this announcement are forward-looking statements. These forward-looking statements involve known and unknown risks and uncertainties and are based on current expectations and projections about future events and financial trends that the Company believes may affect its financial condition, results of operations, business strategy and financial needs. Investors can identify these forward-looking statements by words or phrases such as "may," "will," "expect," "anticipate," "aim," "estimate," "intend," "plan," "believe," "potential," "continue," "is/are likely to" or other similar expressions. The Company undertakes no obligation to update forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to review other factors that may affect its future results in the Company's registration statement and in its other filings with the U.S. Securities and Exchange Commission.
China SXT Pharmaceuticals, Inc.
Feng Zhou, Chief Executive Officer
Email: fzhou@sxtchina.com
View original content:https://www.prnewswire.com/news-releases/china-sxt-pharmaceuticals-inc-announces-share-consolidation-302916765.html
SOURCE China SXT Pharmaceuticals, Inc.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.